Skip to main content
. 2022 Sep;11(9):1847–1857. doi: 10.21037/tlcr-22-160

Table 5. Multivariate analysis for PFS.

Variables HR (95% CI) P value
Age ≥75 years 1.15 (0.78–1.68) 0.490
Female 1.01 (0.75–1.35) 0.960
Poor ECOG PS at first-line initiation 1.04 (0.71–1.53) 0.840
Poor ECOG PS at AMR initiation 1.79 (1.26–2.54) 0.001
Use of platinum plus etoposide at the first-line treatment 1.41 (1.00–1.98) 0.048

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; AMR, amrubicin.